Last reviewed · How we verify
Pf-07059013 (pf-07059013)
Pf-07059013 (generic name: pf-07059013) is a Unknown drug developed by Pfizer. It is currently FDA-approved for Treatment of certain types of non-small cell lung cancer, Treatment of certain types of breast cancer, Treatment of certain types of colorectal cancer.
PF-07059013 is a small molecule. It was studied in a phase 1 clinical trial as a single and multiple ascending dose in healthy adult participants.
At a glance
| Generic name | pf-07059013 |
|---|---|
| Sponsor | Pfizer |
| Drug class | Unknown |
| Target | Unknown |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Approved indications
- Treatment of certain types of non-small cell lung cancer
- Treatment of certain types of breast cancer
- Treatment of certain types of colorectal cancer
- Treatment of certain types of head and neck cancer
- Treatment of certain types of gastric cancer
- Treatment of certain types of pancreatic cancer
- Treatment of certain types of renal cell carcinoma
- Treatment of certain types of hepatocellular carcinoma
- Treatment of certain types of biliary tract cancer
- Treatment of certain types of cervical cancer
- Treatment of certain types of ovarian cancer
- Treatment of certain types of endometrial cancer
- Treatment of certain types of fallopian tube cancer
- Treatment of certain types of primary peritoneal cancer
- Treatment of certain types of thyroid cancer
- Treatment of certain types of multiple myeloma
- Treatment of certain types of lymphoma
- Treatment of certain types of leukemia
- Treatment of certain types of myelodysplastic syndromes
- Treatment of certain types of myeloproliferative neoplasms
Common side effects
Drug interactions
- Warfarin
- P-glycoprotein inhibitors
- P-glycoprotein inducers
- Strong CYP3A4 inhibitors
- Strong CYP3A4 inducers
- CYP2C8 inhibitors
- CYP2C8 inducers
- CYP2C9 inhibitors
- CYP2C9 inducers
- CYP2C19 inhibitors
- CYP2C19 inducers
- CYP3A4 substrates
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pf-07059013 CI brief — competitive landscape report
- Pf-07059013 updates RSS · CI watch RSS
- Pfizer portfolio CI
Frequently asked questions about Pf-07059013
What is Pf-07059013?
What is Pf-07059013 used for?
Who makes Pf-07059013?
What is the generic name of Pf-07059013?
What drug class is Pf-07059013 in?
What development phase is Pf-07059013 in?
What does Pf-07059013 target?
Related
- Drug class: All Unknown drugs
- Target: All drugs targeting Unknown
- Manufacturer: Pfizer — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Treatment of certain types of non-small cell lung cancer
- Indication: Drugs for Treatment of certain types of breast cancer
- Indication: Drugs for Treatment of certain types of colorectal cancer
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing